Evaluating Liraglutide in Alzheimer's Disease

Sponsor
Imperial College London
Study ID
NCT01843075
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Daily subcutaneous injection
  • Placebo — DRUG
    Daily subcutaneous injection

Study Details

This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.

Key Dates

Start date
Jan 31, 2014
Status verified
Jun 2019
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
204 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Daily administration of 1.8 mg liraglutide by subcutaneous injection
  • Placebo Comparator: Placebo
    Daily administration of matched placebo by subcutaneous injection

Primary Outcome Measure

The change in cerebral glucose metabolic rate [ Time Frame: 12 months ]

Related Studies